ARIAD has announced that their ponatinib (Iclusig) trial, which some GIST patients are participating in, has paused new enrollment based on consultations with the FDA regarding patients who experienced particular vascular events. Subject to agreement with the FDA, the trial will be resumed with anticipated changes in dose and other modifications, including eligibility criteria. Patients currently on the ponatinib trial will still be able to participate, but may have their dosage adjusted.
Please click here to learn more about ponatinib. For additional information, visit: http://www.ariad.com.
Share your thoughts on this ponatinib news below and on Facebook and Twitter.